Artivion, Inc. (NYSE:AORT) Q1 2024 Earnings Call Transcript

Lance Berry: Yes. I mean honestly, like on an as adjusted basis, it looks like on an as-reported basis, but that’s because some of the contingent consideration fluctuations. But on an as adjusted basis, it was $48 million, which was fairly consistent with Q4 and I think something in that kind of range is really what we think about as we move throughout the year on an as-adjusted basis, so which should drive some really good leverage year-over-year.

Jeffrey Cohen: Great. And then finally, for us, any commentary on our tissue business with regards to, I know that pulmonary has been strong, but any commentary on the cardiac versus vascular, generally speaking, on pricing or our units out there for the quarter?

Pat Mackin: Yes. We are not going to break out components underneath the kind of the tissue. Obviously, we have talked several quarters in a row about the price increases on cardiac and the volume increases. So, cardiac is definitely driving it, but the whole segment is growing. So – but we are not going to break out pieces.

Jeffrey Cohen: Very clear. Okay. I got with it. Thanks for taking my questions.

Pat Mackin: Thanks Jeff.

Operator: Mr. Mackin, there are no further questions at this time. I would like to turn the floor back over to management for closing comments.

Pat Mackin: No. Thanks for joining for our Q1 call. Again, we are very pleased with the first quarter and 16% top line growth, 16% bottom line growth. We are executing on the pipeline. We have got great products, great data, great sales forces and plan on doing more of the same as the year keeps going. So, appreciate your support and look forward to our next call with you.

Operator: Thank you. This will conclude today’s conference. You may disconnect your lines at this time and thank you for your participation.